Turkish Journal of Medical Sciences
Volume 47

Number 1

Article 20

1-1-2017

Factors associated with the rate of COPD exacerbations that
require hospitalization
RADISA PAVLOVIC
SRDJAN STEFANOVIC
ZORICA LAZIC
SLOBODAN JANKOVIC

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
PAVLOVIC, RADISA; STEFANOVIC, SRDJAN; LAZIC, ZORICA; and JANKOVIC, SLOBODAN (2017) "Factors
associated with the rate of COPD exacerbations that require hospitalization," Turkish Journal of Medical
Sciences: Vol. 47: No. 1, Article 20. https://doi.org/10.3906/sag-1510-142
Available at: https://journals.tubitak.gov.tr/medical/vol47/iss1/20

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences

Turk J Med Sci
(2017) 47: 134-141
© TÜBİTAK
doi:10.3906/sag-1510-142

http://journals.tubitak.gov.tr/medical/

Research Article

Factors associated with the rate of COPD exacerbations that require hospitalization
1,

1

1,2

1,3

Radisa PAVLOVIC *, Srdjan STEFANOVIC , Zorica LAZIC , Slobodan JANKOVIC
1
Faculty of Medical Science, University of Kragujevac, Kragujevac, Serbia
2
Clinic of Pulmonary Diseases, University Clinical Center Kragujevac, Kragujevac, Serbia
3
Department of Clinical Pharmacology, University Clinical Center Kragujevac, Kragujevac, Serbia
Received: 30.10.2015

Accepted/Published Online: 14.05.2016

Final Version: 27.02.2017

Background/aim: Exacerbations are key events in chronic obstructive pulmonary disease (COPD). Frequent exacerbations occurring
during the natural course of COPD lead to deterioration of health-related quality of life and are major causes of morbidity and mortality.
The aim of this study was to identify factors independently associated with frequent severe exacerbations of COPD that require
hospitalization.
Materials and methods: A case-control study was performed to analyze risk factors and frequency of severe exacerbations, which were
defined by the GOLD guideline criteria. Stepwise multivariate regression was used to determine the significant predictors of frequent
exacerbations.
Results: Results revealed five independent predictors of frequent exacerbations: age, length of hospital stay, FEV1/FVC ratio, CRP level
above 10 mg/L, and respiratory comorbidities.
Conclusion: COPD patients should be more carefully assessed in terms of age, length of hospital stay, FEV1/FVC ratio, CRP level, and
respiratory comorbidities. Patients under 65 years of age with respiratory comorbidities, longer hospital stay, lower FEV1/FVC ratio and
CRP of <10 mg/L are more prone to experiencing a minimum of one additional hospitalization in the following year. Patients could
spend less time in the hospital environment and increase their quality of life by adjusting these risk factors for hospitalization due to
COPD.
Key words: Chronic obstructive pulmonary disease, severe exacerbation, exacerbation frequency, risk factors, hospitalization

1. Introduction
Chronic obstructive pulmonary disease (COPD) is a both
treatable and preventable clinically heterogeneous syndrome,
with prevalence somewhat lower than 6% (1). Frequent
exacerbations occurring during the natural course of COPD
lead to deterioration of health-related quality of life and
are major causes of morbidity and mortality (2). They have
high prevalence and high impact on disease progression and
prognosis; they accelerate the decline in lung function, have
a negative impact on quality of life, promote frequent clinic
visits and hospitalizations, and are responsible for a large
proportion of the health care costs (3–5).
Recently, a distinct subgroup of patients named “frequent
exacerbators” was introduced (2,3). These are the patients
with comparable lung function impairment to that of other
patients, but with more frequent exacerbations. Although
this frequent exacerbator phenotype occurs regardless of
GOLD stage, the exacerbation rate increases with severity
of the disease (3–8).
* Correspondence: rpavlovic@medf.kg.ac.rs
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To date, the history of exacerbations has been
recognized as the single best predictor of future events
(3,9). Obvious correlation has been revealed between
decreased lung function and disease severity (10), elevated
white-cell count (3,11), hematocrit level of <41% (12),
BODE score, sex, age, smoking status, body mass index,
presence of cardiovascular comorbidity (13,14), influenza
and 23-valent pneumococcal immunizations (5), and
frequency of severe exacerbations of COPD. However,
other studies failed to confirm the influence of other risk
factors such as blood glucose level, FEV1% predicted,
long-acting bronchodilator use, or inhaled or systemic
steroid use (2,15).
Prevention of exacerbations is a key component
of strategies for COPD treatment and that is why it is
important to understand the risk factors, incidence,
characteristics, and effects of exacerbations in patients with
COPD. Nevertheless, it is important to identify patients at
risk for frequent exacerbations at various levels of disease
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severity (16). The aim of this study was to identify factors
associated with frequent severe exacerbations of COPD
that require hospitalization.
2. Materials and methods
2.1. Study subjects
In this retrospective case-control study we examined the
risk factors and frequency of severe exacerbations in COPD
patients that were hospitalized due to index exacerbation
of COPD in the tertiary care university hospital Clinical
Center of Kragujevac during a 3-year period (2010–2012).
A total of 512 individual medical records were reviewed
representing all hospitalized patients with COPD during
the study period. We analyzed both female and male
patients above 18 years old with established diagnosis of
COPD, and 174 patients fulfilled these criteria and were
included in further analysis. A group of 64 subjects who
were frequent exacerbators formed the study population
while 110 patients were in the control group. The
remaining patients were excluded from the study due to
incomplete patient files and several conditions that reduce
lung function: associated restrictive disorders (interstitial
fibrosis, tuberculosis, etc.), a history of lung cancer,
previous lung surgery, recent myocardial infarction, or
pulmonary embolism, as described elsewhere (2). For the
purposes of this study, respiratory comorbidities were
defined as acute or chronic, partial or global respiratory
failure.
The study protocol was approved by the ethical board
of the Clinical Center of Kragujevac.
2.2. COPD exacerbations
COPD exacerbation was defined by the criteria of
the GOLD guidelines (1). We analyzed only severe
exacerbations that required hospitalization.
2.3. Statistical analysis
Baseline demographic characteristics of the patients were
described by means ±
 SD for continuous variables and
frequency (percentages) for categorical variables. In order
to determine differences in the mean values of
 continuous
variables with normal distribution of values, the parametric
Student t-test was used, and its nonparametric alternative,
the Mann–Whitney test, was used if data did not follow
a normal distribution. Differences between groups in
the incidence of certain categories were determined by
chi-square test or the Fisher test of real likelihood for
low frequencies. Potential predictors of the observed
outcome were determined using binary logistic regression,
and values of the crude and adjusted odds ratios with
corresponding confidence intervals of 95% were used to
express the strength of correlations. All data were analyzed
using SPSS 20 where P < 0.05 was considered statistically
significant.

3. Results
This case-control study was conducted on 174 patients
divided into two groups. The difference in age and
mean level of BMI between the groups was statistically
significant (P = 0.005, P = 0.018). Patients who had at least
two exacerbations during the study period stayed longer
in the hospital (P = 0.001) and had lower values of lung
function parameters (FEV1 predicted %, FEV1/FVC ratio:
P < 0.001, P = 0.001). A value of FEV1 of <50% was also
more often noted in the group of frequent exacerbators
(P = 0.007). Respiratory comorbidity rates were different
between the groups (P = 0.014). Furthermore, patients in
the control group had higher serum levels of CRP (P =
0.005) and higher frequency of CRP level above 10 mg/L
(P = 0.012). We also found differences in the erythrocyte
count (P = 0.008) and the rate of prescribing preventive
therapy (P = 0.047). Baseline demographic characteristics
of the patients are shown in Table 1.
These baseline assessments were used as a starting point
to analyze factors associated with frequent exacerbators.
The best potential predictors of future exacerbations were
age, length of hospital stay, FEV1 level, FEV1 <50%, FVC,
FEV1/FVC ratio, respiratory comorbidities, frequency of
CRP level above 10 mg/L, number of erythrocytes, and
percentage of prescribed preventive therapy. Other results
of univariate logistic regression are shown in Table 2.
Factors that were associated with frequent exacerbators
were assessed by a stepwise multivariate regression
model. Results of this analysis revealed five independent
predictors of frequent exacerbations: age, length of
hospital stay, FEV1/FVC ratio, CRP level above 10 mg/L,
and respiratory comorbidities (Table 3).
4. Discussion
The results from our study have shown that the
patients under 65 years with the presence of respiratory
comorbidities, longer hospital stay, lower FEV1/FVC
ratio, and CRP <10 mg/L are more prone to experience
a minimum of one additional hospitalization in the
following year. Several studies have shown the association
of a range of variables with frequency of different COPD
exacerbations (3–14).
We have noticed that age is associated with future
exacerbations. Interestingly, it seems that older patients
are less prone to experiencing at least two exacerbations
in a year, which is inconsistent with a number of previous
reports. Some studies failed to explain the influence of
age on COPD exacerbations. Previous data showed that
an increase in age of 10 years could produce about 3.5%
increase in exacerbation rate in the following year (17).
Older patients (11,18) and the patients above 65 years of age
also had greater risk for repeated hospitalizations (19,20).
Reexacerbation in 90 days was shown to be associated with
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Table 1. Baseline characteristics of the patients.
Variables

Cases (n = 64)

Controls (n = 110)

Test

P-value

Age, years

64.9 ± 10.8

68.9 ± 8.6

Z = –2.814

0.005

Sex, male (%)

67.2 (n = 43)

68.2 (n = 75)

χ² = 0.018

0.892

BMI, kg/m2 a

26.8 ± 6.3

24.2 ± 5.7

Z = –2.369

0.018

Current smoker (%)

48.4 (n = 31)

52.7 (n = 58)

χ² = 0.298

0.585

Smoking (pack-years)

36.7 ± 26.1

36.5 ± 25.4

Z = –0.298

0.766

LOH stay

15.1 ± 6.4

11.9 ± 4.4

Z = –3.192

0.001

FEV1, predicted (%) c

36.5 ± 14.3

45.4 ± 15.5

Z = –3.659

<0.001

FEV1 <50% (%)

82.8 (n = 53)

63.6 (n = 70)

χ² = 7.181

0.007

FVC

80.4 ± 21.1

88.5 ± 22.2

T = 2.259

0.025

FEV1/FVC ratio, (%) c

45.1 ± 9.9

51.1 ± 10.6

Z = –3.224

0.001

Comorbidities (%)

92.2 (n = 59)

88.2 (n = 97)

χ² = 0.700

0.403

Respiratory comorbidities (%)

73.4 (n = 47)

54.5 (n = 60)

χ² = 6.098

0.014

Cardiovascular comorbidities (%)

57.8 (n = 37)

63.6 (n = 70)

χ² = 0.580

0.446

CRP mg/L d

27.3 ± 55.8

51.9 ± 68.7

Z = –2.815

0.005

b

c

CRP >10 mg/L (%)

39.1 (n = 25)

60 (n = 66)

χ² = 6.295

0.012

Leukocytes (×109/L)

10.5 ± 3.8

10.6 ± 4.3

Z = –0.012

0.990

Erythrocytes (×1012/L)

4.8 ± 0.7

4.5 ± 0.6

T = –2.666

0.008

Hematocrit

0.48 ± 0.07

0.46 ± 0.07

T = 0.481

0.149

Hematocrit <41% (%)

17.2 (n = 11)

20 (n = 22)

χ² = 0.208

0.648

Blood glucose (mmol/L)

7.6 ± 2.6

7.8 ± 4..8

Z = –0.368

0.713

Prescribed preventive therapy (%) e

79.7 (n = 51)

65.5 (n = 72)

χ² = 3.956

0.047

BMI - body mass index.
LOH - length of hospital stay.
c
Parameters of lung function: FEV1 - forced expiratory volume at first second; FVC - forced vital capacity.
d
CRP - C-reactive protein.
e
Prescribed preventive therapy - long acting bronchodilators- LABAs, LAMA, theophylline, and inhaled steroids.
a

b

age (21). On the contrary, other authors observed high
readmission rates for patients younger than 65 years (22),
or did not suggest that age could be a predictor variable
(15). Our results showed that in the population of patients
less than 65 years of age (n = 69) in both studied groups,
48 patients (69.9%) had respiratory comorbidities present.
Further, out of this number, 27 patients (84.4%) were in the
case group compared to 21 (56.8%) in the control group of
patients, showing a significant difference (P = 0.013) (data
not shown). This finding indicates that patients under 65
years with respiratory comorbidities have more chance of
experiencing a minimum of two hospitalizations in a year.
In our circumstances, patients also do not often adhere
to prescribed therapy due to poor socioeconomic status
and scant health education. Limited knowledge often
increases fear for health. It is possible that older patients
from our study used preventive therapy prescribed during
the index hospitalization (long-acting bronchodilators-
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LABAs, LAMA, theophylline, and inhaled steroids), more
often due to more pronounced fear for their own health.
Nevertheless, our multivariate analysis did not show a
predictive value of prescribed preventive therapy, although
its efficacy for prevention of acute exacerbations has
been well established (17,23,24). Treatment with inhaled
LABAs and ICS decreased exacerbation frequency in a
population of COPD patients older than 70 years (21). In
our study, preventive therapy was prescribed more often to
the frequent exacerbators group, which is a younger group
of patients and less adherent to prescribed medication.
This finding could contribute to confounding since
we had limited information about compliance. Similar
observations have been presented previously (2). Further
examinations are needed to confirm this claim.
Higher exacerbation frequency is more likely to be
reported in patients with longer length of hospital stay
(LOH) according to our results. Prolonged time spent in
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Table 2. Univariate analysis of possible predictors of frequent severe COPD exacerbations.
Variables

Odds ratio (95% CI)

P -value

Age, years

0.948 (0.917–0.980)

0.002

Sex

1.047 (0.542–2.021)

0.892

BMI, kg/m2 a

1.054 (1.000–1.111)

0.05

Current smoker (%)

0.842 (0.455–1.561)

0.585

Smoking (pack-years)

1.005 (0.993–1.017)

0.426

LOH stay

b

1.121 (1.048–1.199)

0.001

FEV1, predicted (%) c

0.962 (0.940–0.985)

0.001

FEV1 <50 % (%)

2.753 (1.292–5.868)

0.009

FVC

0.983 (0.968–0.998)

0.027

FEV1/FVC ratio, (%) c

0.952 (0.923–0.982)

0.002

Comorbidities (%)

1.581 (0.537–4.661)

0.406

Respiratory comorbidities (%)

2.304 (1.179–4.501)

0.015

Cardiovascular comorbidities (%)

0.783 (0.417–1.470)

0.447

CRP mg/L d

0.994 (0.989–1.000)

0.044

CRP >10 mg/L

0.427 (0.227–0.803)

0.008

Leukocytes (×109/L)

0.988 (0.919–1.063)

0.749

c

Erythrocytes (×10 /L)

1.938 (1.170–3.208)

0.01

Hematocrit

27.605 (0.303–2512.921)

0.149

Hematocrit <41% (%)

0.830 (0.373–1.848)

0.648

Glycemia (mmol/L)

0.972 (0.890–1.062)

0.533

Prescribed preventive therapy (%) e

2.071 (1.003–4.274)

0.049

12

BMI - body mass index.
LOH - length of hospital stay.
c
Parameters of lung function: FEV1 - forced expiratory volume at first second; FVC - forced
vital capacity.
d
CRP - C-reactive protein.
e
Prescribed preventive therapy - long acting bronchodilators- LABAs, LAMA, theophylline, and
inhaled steroids.
a

b

the hospital due to COPD exacerbation may indicate more
fragile patients with comorbidities like respiratory disease,
heart failure, or diabetes (25–27), who are more susceptible
to exacerbations. Thus, these patients could more often
experience at least two exacerbations in a year. Similar
findings have been reported earlier (28,29), suggesting
that ischemic heart disease might contribute to treatment
failure, while elevated blood sugar level might support the
growth of pathogens in the airway, promote inflammation,
and increase the frequency of exacerbations (29). At the
same time, in our study, cardiovascular comorbidities
and glucose level were not associated with frequent
exacerbations. Other authors have outlined the same
conclusion as we noticed regarding LOH, despite the fact
that their basic results were the opposite: shorter LOH was
associated with repeated hospitalization (25). As suggested

before, prolonged LOH is associated with disease severity
(25,29), which is aligned with our findings showing
that patients with more exacerbations had more severe
forms of COPD, additionally aggravated by respiratory
comorbidities (as shown in Table 1). Furthermore, these
comorbidities may impair lung function additionally,
disturb the overall health status, and limit the patient’s
ability to cope with acute illness and therefore increase
the susceptibility to repeated hospitalization (25,29).
Respiratory comorbidities were more often reported among
the cases in our study. Their association with frequent
exacerbations was also confirmed after adjustment (as
shown in Table 3).
Impairment of lung function as well as treatment
response has been well established as a risk factor for
frequent exacerbations (6,8,13,30), which is not in
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Table 3. Stepwise multivariate analysis of possible predictors of frequent severe COPD
exacerbations.
Variables
Age, years

Odds ratio (95% CI)

P-value

0.954 (0.918–0.991)

0.015

a

1.128 (1.047–1.214)

0.001

FEV1/FVC ratio (%) b

0.955 (0.923–0.988)

0.007

CRP >10 mg/L

0.387 (0.185–0.808)

0.011

Respiratory comorbidities (%)

2.241 (1.023–4.907)

0.044

LOH stay

LOH - length of hospital stay.
Parameters of lung function: FEV1 - forced expiratory volume at first second; FVC forced vital capacity.
a

b

accordance with our results. If measuring spirometry
during a clinically stable period, at least 2 months after
hospitalization, lower FEV1 values would be associated
with a higher risk of readmission (31). Moreover, patients
who experienced a 2-month treatment (ICS/LABA/
LAMA) response and FEV1 improvement had greater
reductions in exacerbation risk in the following year
(30). We found no association between FEV1 predicted,
FEV1 <50% (GOLD staging III and IV), and exacerbation
frequency in multivariate regression, although both
variables showed significance in univariate analysis.
Our study is not the only one that reported a lack of
relationship between decreased lung function and
exacerbation frequency (2,25,31). Explanations proposed
earlier suggest that this finding may be due to relatively
small variations in FEV1 in the studied population of 43
± 16 (25) and the spirometry testing being performed
during hospitalization, not in a stable form of the disease
(31). Similar variations in FEV1 values measured during
hospitalization were noticed in our study: 36.5 ± 14.3 and
45.4 ± 15.5 (as shown in Table 1). Our results indicated
that the FEV1/FVC ratio might be a better predictor of
future events during the course of COPD. Similar, the
exacerbation onset in the next 6 months is associated with
lower FEV1/FVC ratios (32). Recent observations showed
univariate association of similar parameters, FEV1 %
predicted and FEV1/FVC, with frequent exacerbations
that were lost in multivariate analysis for both variables
(16), while others found no difference in FEV1 %
predicted and FEV1/IVC between groups (33). Many
guidelines suggest the FEV1/FVC ratio for assessment of
the airway obstruction. However, interpretation of this
test could be challenging since it depends not only on the
degree of airflow limitation estimated based on the value
of FEV1, which was significant lower in the case group
of patients in our study, but it also depends on the value
of FVC. Since FVC represent a volume of exhaled air, its
value is strongly influenced by duration of expiratory time.
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It was established that the longer the expiratory time is,
the higher the value of FVC, and vice versa (34). Patients
with airflow obstruction find it difficult to empty their
lungs and hence need more time for exhalation, as do
older patients. In our study, the case group of patients had
significantly lower levels of FEV1, FVC, and FEV1/FVC
ratio. This result suggests that expiratory flow was slower
in the control group of patients since they had significantly
higher FVC values (as shown in Table 1). During air
exhalation, expiratory muscles are activated and therefore
patients could get tired during spirometry testing, which
is more frequent in patients with obstruction but also
in older patients. This could explain the significant
difference in FVC values in favor of the control group,
which was a significantly older group (as shown in Table
1). However, valid expiration during spirometry testing is
considered to be one lasting at least 6 s (35), suggesting
that our hypothesis could be confirmed or invalidated by
assessing values of FEV6 measurements, which is a more
stable indicator of expiration accuracy (36) independently
related to annual lung function decline (37) and eliminates
the potential age factor in interpretation of FVC values.
Further studies are needed to investigate this issue. It
would also be useful to determine the cut-off values of the
FEV1/FVC ratio, which could be helpful in anticipating
the course of COPD. Our results suggested that younger
patients suffering from COPD with lower FEV1, FVC, and
FEV1/FVC ratio have more chance of having at least two
hospitalizations in a year.
Interestingly, we found a significant difference in
CRP levels in favor of the control group. Correlation
between serum CRP levels and clinical parameters is still
under discussion and the conclusions are not definitive.
It was noticed that CRP level correlates with degree of
pulmonary inflammation during the stable phase of COPD
and could have a predictive value in the COPD course
(38), with increased incidences of hospitalization due to
COPD in individuals with higher levels of CRP (39,40).
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Concentration of CRP level is also found to be related
to the presence of airflow obstruction in COPD patients
(41) and lung function parameters FEV1 and FVC (42),
while authors of other studies failed to demonstrate this
association (43,44). However, all of these studies observed
patients in the stable form of the disease and most of
them considered CRP level as a categorical variable (CRP
<3 mg/L versus CRP >3 mg/L). In the present study
we considered CRP level as a continuous variable and
observed a pool of patients in exacerbation, not in the
stable form of the disease. Since we could not confirm
a predictor value for CRP level as a continuous variable
(CRP mg/L) in univariate regression analysis (as shown
in Table 2), we performed additionally analyses with CRP
level as a categorical variable (CRP <3 mg/L versus CRP
>3 mg/L) with no statistical difference (data not shown)
and also as CRP <10 mg/L versus CRP >10 mg/L, since
in healthy young adult volunteer blood donors, the 99th
percentile of CRP is established at a level of 10 mg/L (45).
Interestingly, second analyses showed a higher frequency
of CRP of >10 mg/L in the infrequent exacerbators group of
patients, contrary to previous results (38). Concentration
of CRP is expected to be higher in frequent exacerbator
groups of patients due to the enhanced inflammatory
response (40). It was reported that CRP is the most
variable biomarker among several potential biomarkers in
COPD (46). Accordingly, it is possible that these variations
of CRP concentration between the stable phase of COPD
and exacerbation are more pronounced in the control
group of patients. This group of patients could have less
enhanced inflammatory response and thus less elevated
CRP concentration during the stable phase of COPD, but
during exacerbations, the control group of patients could
have a greater increase of CRP concentration and more

elevated values of this parameter than the case group of
patients. Since they were an older group of patients with
possible impairment of the immune system, and since CRP
levels can predict bacterial exacerbation in patients with
COPD (39), it is possible that bacterial infection was more
often present in the control group of patients, causing a
greater increase of CRP. This more intensive inflammatory
response during exacerbation could somehow help with
eradication of microorganisms and postpone the next
exacerbation.
We are aware of several limitations of our study. First,
since bronchodilator testing was conducted for only a
small number of patients, we used prebronchodilator
values instead, which is in contrast to guideline
recommendations (1). It remains unclear how this would
affect the outcomes. Second, the case-control approach
predisposes the present study to recall bias. Finally, the
number of patients’ medical files that we included in the
study could be perceived as modest and may not represent
the COPD population at large.
Despite these limitations, our study suggests that age,
length of hospital stay, FEV1/FVC ratio, CRP level, and
the presence of respiratory comorbidities could be used to
anticipate future exacerbations requiring hospitalization
of COPD patients. Adherence to prescribed therapy also
influences the course of COPD. Concentration of CRP has
predictive value for COPD exacerbation rates and should
be measured during both the stable form of COPD and
also during exacerbation. Learning to recognize, adjust,
diminish, or eliminate these and a number of other risk
factors may improve patient quality of life and help them
to spend less time in hospital environments. Further
prospective studies are necessary to resolve the significance
of all potential predictors of the COPD exacerbation rate.
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